Related Experiment Video

Updated: Jun 14, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma

Weijing Zhang1, Xuechuan Hong2, Yuling Xiao3

  • 1School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|April 5, 2025
PubMed

Insights

Hepatocellular carcinoma (HCC) treatment with sorafenib offers benefits but faces resistance. Research explores mechanisms and new strategies to improve outcomes for advanced liver cancer patients.

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide.
  • Advanced HCC often precludes curative treatments like surgery or transplantation.
  • Sorafenib, an FDA-approved multi-target kinase inhibitor, is a standard treatment for advanced HCC.

Purpose of the Study:

  • To review the role of sorafenib in advanced HCC treatment.
  • To discuss sorafenib's therapeutic mechanisms and resistance pathways.
  • To explore novel therapeutic strategies for improving HCC patient outcomes.

Main Methods:

  • Literature review of sorafenib in advanced HCC.
  • Analysis of mechanisms of action and resistance to sorafenib.
  • Exploration of emerging therapeutic approaches.

Main Results:

  • Sorafenib provides clinical benefits but resistance and side effects limit long-term efficacy in less than half of patients.
  • Understanding resistance mechanisms is crucial for optimizing treatment.
  • Combination therapies and novel agents are under investigation.

Conclusions:

  • Sorafenib remains a key therapy for advanced HCC, but challenges persist.
  • Further research into resistance mechanisms and combination strategies is essential.
  • Improving sorafenib efficacy and overcoming resistance are critical for better HCC patient outcomes.
Keywords:
Drug resistanceHepatocellular carcinomaSorafenibTherapeutic strategy

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K